MEDICINE Buspring 2020 • Volume 104Et • Number 4 In
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Origin of Bimaristans (Hospitals) in Islamic Medical History
The Origin of Bimaristans (Hospitals) in Islamic Medical History IMPORTANT NOTICE: Author: Dr. Sharif Kaf Al-Ghazal Chief Editor: Prof. Mohamed El-Gomati All rights, including copyright, in the content of this document are owned or controlled for these purposes by FSTC Limited. In Deputy Editor: Prof. Mohammed Abattouy accessing these web pages, you agree that you may only download the content for your own personal non-commercial Associate Editor: Dr. Salim Ayduz use. You are not permitted to copy, broadcast, download, store (in any medium), transmit, show or play in public, adapt or Release Date: April 2007 change in any way the content of this document for any other purpose whatsoever without the prior written permission of FSTC Publication ID: 682 Limited. Material may not be copied, reproduced, republished, Copyright: © FSTC Limited, 2007 downloaded, posted, broadcast or transmitted in any way except for your own personal non-commercial home use. Any other use requires the prior written permission of FSTC Limited. You agree not to adapt, alter or create a derivative work from any of the material contained in this document or use it for any other purpose other than for your personal non-commercial use. FSTC Limited has taken all reasonable care to ensure that pages published in this document and on the MuslimHeritage.com Web Site were accurate at the time of publication or last modification. Web sites are by nature experimental or constantly changing. Hence information published may be for test purposes only, may be out of date, or may be the personal opinion of the author. -
The Contemporary Physician Leader
White Paper The Contemporary Physician Leader By Miles Snowden, MD Optum www.optum.com/aco 800.765.6619 Page 1 The Contemporary Physician Leader White Paper The “Triple Aim”—a term coined by the Institute of Healthcare Improvement to embody the goals of better care, controlled costs and improved health—has become a rallying cry in the health care industry.1 As the health care market in the United States focuses on changing incentives to accomplish the Triple Aim, a new generation of better improved leaders is needed who can clinically and financially transform provider care health organizations. Chief medical officers (CMOs) and other physician leaders Triple in hospitals, group practices and integrated delivery systems have unique Aim qualifications that can allow them to take ownership of these important changes. However, their success in this new era will require that they controlled evolve away from the roles they have traditionally played. costs This paper will share the perspectives of five physician leaders who represent the contemporary physician leader. In doing so, it will discuss the skill set, experience and qualities physician executives need to lead their organizations’ conversion from volume to value. Physician executive roles continue to evolve The role of the physician executive has evolved over the years. The traditional physician leader in a hospital setting is a medical director. Medical directors were sometimes employed by facilities but often were independent, affiliated doctors. These providers served as liaisons between hospitals and the credentialed medical staff. They worked closely with hospital administrators but rarely had a seat at the executive table. -
Study Protocol
Protocol Number: VXA-G11-201.1 ________________________________________________________________________________ Clinical Study Protocol Protocol Title: Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model Protocol Number: VXA-G11-201.1 IND Sponsor: WCCT Global 3545 Howard Way, Costa Mesa, CA 92626 Maria Apkarian Vice President, Early Clinical Development Email: [email protected] Phone: 714-252-0700; ext: 1019 Funding Sponsor: Vaxart, Inc. Funding Sponsor POC: David N. Taylor, MD Chief Medical Officer Vaxart, Inc. 400 Oyster Point Blvd., Suite 222 South San Francisco, CA 94080 Email: [email protected] Mobile phone: 919-349-6109 Protocol Version Number: 1.1 Amendment 1 Date: 21 September 2018 Confidentiality Statement This document is confidential and is to be distributed for review only to investigators, potential investigators, consultants, study staff, and applicable independent ethics committees or institutional review boards. The contents of this document shall not be disclosed to others without written authorization from Vaxart (or others, as applicable), unless it is necessary to obtain informed consent from potential study subjects. SIGNATURE PAGE/STATEMENT OF COMPLIANCE Version 1.1 Confidential Page 1 of 50 Date: 21Sept 2018 Protocol Number: VXA-G11-201.1 ________________________________________________________________________________ Protocol Title: Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model Protocol Number: VXA-G11-201.1 Vaxart, Inc. ______________________________ ________________ David Taylor Date Chief Medical Officer The trial will be conducted in accordance with the International Conference on Harmonisation (ICH) E6 and the Code of Federal Regulations on the Protection of Human Subjects (45 CFR Part 46). -
Placebos, Randomization and Financial Incentives
1 Placebos, randomization, and financial incentives – oh my! Balancing ethical considerations in clinical research Stephanie Kraft, JD and Kathryn Porter, JD, MPH ITHS Bioethics Core Treuman Katz Center for Pediatric Bioethics Seattle Children’s Research Institute Learning Objectives 1• Describe eight benchmarks for ethical clinical research 2 Discuss how empirical data illustrates limitations of ethics regulations of randomization 3 Identify elements of a proposed research study that warrant ethical deliberation Outline 1 Introduction to a framework for ethical clinical research 2 Case studies: what to do when benchmarks conflict 3 Group discussion and practice applying the framework Why research ethics? Please vote: Do you consider yourself an ethically responsible researcher? Why research ethics? “Isn’t ethics for people who have bad motivations?” • Not just about preventing egregious violations - no such thing as the “ethics police” • Also offers guidance, identifies potential challenges Why research ethics? Please vote: Have you ever faced an ethical challenge in your research that was outside the scope of the IRB? Why research ethics? “Aren’t there regulations for that?” • Research ethics analysis helps flesh out responsibilities above the regulatory floor Why research ethics? Please vote: Have you ever raised an ethics issue to a colleague or PI? Why research ethics? “Is it really my job to worry about ethics?” • Yes! • Ethics analysis is important for all research team members • Framework can empower researchers to identify and -
Human Challenge Trials for Vaccine Development: Regulatory Considerations
POST ECBS Version ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 Human Challenge Trials for Vaccine Development: regulatory considerations © World Health Organization 2016 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. -
Chief Physician and Surgeon
OPEN SPOT CONTINUOUS EXAMINATION FOR DEPARTMENT OF STATE HOSPITALS- ATASCADERO, COALINGA, METROPOLITAN, NAPA, AND PATTON CHIEF PHYSICIAN AND SURGEON www.dsh.ca.gov The State of California is an equal opportunity employer to all, regardless of age, ancestry, color, disability (mental and physical), exercising the right to family care and medical leave, gender, gender expression, gender identity, genetic information, marital status, medical condition, military or veteran status, national origin, political affiliation, race, religious creed, sex (includes pregnancy, childbirth, breastfeeding and related medical conditions), and sexual orientation. It is the objective of the State of California to achieve a drug-free state workplace. Any applicant for State employment will be expected to behave in accordance with this objective because the use of illegal drugs is inconsistent with the law of the State, the rules governing civil service, and the special trust placed in public servants. EXAMINATION TYPE This is an open examination for the Department of State Hospitals. Examination and/or Employment Applications will not be accepted on a promotional basis. Career credits do not apply. HOW TO APPLY Please submit an Examination and/or Employment Application (STD. 678) form to the address indicated below. DO NOT SUBMIT EXAMINATION AND/OR EMPLOYMENT APPLICATION FORMS TO THE CALIFORNIA DEPARTMENT OF HUMAN RESOURCES. NOTE: All Examination and/or Employment Application forms must include: “to” and “from” dates (month/day/year); time base; and civil service class titles. Examination and/or Employment Application forms received without this information will be rejected. Resumes will not be accepted in lieu of a completed Examination and/or Employment Application (STD. -
A Toddler PCV Booster Dose Following 3 Infancy Priming Doses Increases
Vaccine 36 (2018) 2774–2782 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage ⇑ Ron Dagan a, , Shalom Ben-Shimol a,b, Birgit Simell c, David Greenberg a,b, Nurith Porat a,b, Helena Käyhty d, Noga Givon-Lavi a,b a The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel b The Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer-Sheva, Israel c Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland d Department of Vaccination and Immune Protection, National Institute for Health and Welfare (THL), Helsinki, Finland article info abstract Article history: Background: We compared PCV7 serological response and protection against carriage in infants receiving Received 7 January 2018 3 doses (2, 4, 6 months; 3+0 schedule) to those receiving a booster (12 months; 3+1). Received in revised form 30 March 2018 Methods: A prospective, randomized controlled study, conducted between 2005 and 2008, before PCVs Accepted 3 April 2018 were implemented in Israel. Healthy infants were randomized 1:1:1 to receive 3+1, 3+0 and 0+2 (control Available online 11 April 2018 group; 12, 18 months doses). Nasopharyngeal/oropharyngeal swabs were obtained at all visits. Serum serotype-specific IgG concentrations and opsonic activities (OPA) were measured at 2, 7, 13 and 19 Keywords: months. This study was registered with Current Controlled Trials, Ltd. ISRCTN28445844. Pneumococcal conjugate vaccines Results: Overall, 544 infants were enrolled: 3+1 (n = 178), 3+0 (n = 178) and 0+2 (n = 188). -
The Typhoid Vaccine Acceleration Consortium
Vaccine 35 (2017) 5081–5088 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Conference report The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK ⇑ James E. Meiring a, , Malick Gibani a, the TyVAC Consortium Meeting Group: Buddha Basnyat a,b, Adwoa D. Bentsi-Enchill c, John Clemens d, Thomas C. Darton e,f, Kashmira Date g, Gordon Dougan h, Denise Garrett i, Bradford D. Gessner j, Melita A. Gordon k,l, Robert S. Heyderman m, Joachim Hombach c, Karen L. Kotloff n, Myron M. Levine n, Stephen P. Luby o, Vadrevu Krishna Mohan p, Anthony A. Marfin q, Kim Mulholland r, Kathleen Neuzil n, Virginia E. Pitzer s, Andrew J. Pollard e, Firdausi Qadri d, David Salisbury t, Anita Zaidi u a Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal b Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom c Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland d International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b), Dhaka, Bangladesh e Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom f The Hospital for Tropical Diseases, Wellcome Trust Major Overseas -
Credentials Policy
CREDENTIALS POLICY Deer Valley Medical Center John C. Lincoln Medical Center Scottsdale Osborn Medical Center Scottsdale Shea Medical Center Scottsdale Thompson Peak Medical Center Proposed April 11, 2018 Horty, Springer & Mattern, P.C. 259050.19 CREDENTIALS POLICY TABLE OF CONTENTS PAGE 1. GENERAL ..........................................................................................................................1 1.A. TIME LIMITS .........................................................................................................1 1.B. DELEGATION OF FUNCTIONS ..........................................................................1 1.C. CONFIDENTIALITY AND PEER REVIEW PROTECTION ...............................1 1.C.1. Confidentiality .............................................................................................1 1.C.2. Peer Review Protection ................................................................................2 1.D. INDEMNIFICATION..............................................................................................2 1.E. DEFINITIONS .........................................................................................................2 2. QUALIFICATIONS, CONDITIONS, AND RESPONSIBILITIES .............................7 2.A. QUALIFICATIONS ................................................................................................7 2.A.1. Threshold Eligibility Criteria .......................................................................7 2.A.2. Extension of Time Frame to Satisfy Board -
Uk Healthcare Medical Staff Bylaws
UNIVERSITY OF KENTUCKY UK HEALTHCARE MEDICAL STAFF BYLAWS ADOPTED AND APPROVED OCTOBER 11, 2010 AMENDED AND RESTATED DECEMBER 9, 2019 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS ........................................................................................................... 1 ACGME ............................................................................................................................................. 1 Administration ................................................................................................................................... 1 Board of Trustees or Board ................................................................................................................ 1 Chair .................................................................................................................................................. 1 Chandler Hospital .............................................................................................................................. 1 Children’s Hospital ............................................................................................................................ 2 Chief Clinical Officer ........................................................................................................................ 2 Chief Medical Officer(s) .................................................................................................................... 2 Chief Nurse Executive ...................................................................................................................... -
Medical Books in the Byzantine World
EIKASMOS Quaderni Bolognesi di Filologia Classica Studi Online, 2 MEDICAL BOOKS IN THE BYZANTINE WORLD EDITED BY BARBARA ZIPSER BOLOGNA 2013 Medical books in the Byzantine world edited by BarbaraZipser Bologna 2013 o Eikasmós Online II ISSN 2282-2178 In memoriam David Bennett y Table of Contents Acknowledgments . vii List of figures. .xi List of abbreviations . xii 1. Prefatory note: the uses of medical manuscripts Peregrine Horden (RHUL and Oxford). .1 2. Byzantine medicine, genres, and the ravages of time Vivian Nutton (UCL) . 7 3. Disease and where to treat it: a Byzantine vade mecum Dionysios Stathakopoulos (KCL) . 19 4. Two Latin Pre-Salernitan medical manuals, the Liber passionalis and the Tereoperica (Ps. Petroncellus) Klaus-Dietrich Fischer (Mainz) . 35 5. The fate of a Greek medical handbook in the Medieval West: the Intro- duction, or the Physician ascribed to Galen Caroline Petit (ICS) . 57 6. Aristotle and the Caliph's Dream. Aspects of medical translations David Bennett (formerly NHS and RHUL) . 79 7. `Syriac' plant names in a fifteenth century Greek glossary (From the Wellcome Library Books and Manuscripts) Nikolaj Serikoff (Wellcome Library). .97 8. The Reception of Galen's Art of medicine in the Syriac Book of medicines Siam Bhayro (Exeter) . 123 9. Medieval hospital formularies: Byzantium and Islam compared Peregrine Horden (RHUL and Oxford) . 145 10. Cancerous cells, Neanderthal DNA and the tradition of Byzantine me- dicine. Textual criticism in philology and genomics Florian Markowetz (Cancer Research UK Cambridge and University of Cambridge) and Barbara Zipser (RHUL) . 165 Acknowledgements This volume originates from a conference on Byzantine Medical Manuals in Context, held in central London on the 19th of September 2009. -
JOURNAL of REHABILITATION the International JRM MEDICINE Non-Profit Journal VOL
JOURNAL OF REHABILITATION The International JRM MEDICINE Non-profit Journal VOL. 51. OCTOBER 2019 6th Baltic and North Sea Conference on Physical and Rehabilitation Medicine Rehabilitation towards future health and participa- tion - an evidence-based strategy Oslo, Norway, October 9–10, 2019 ABSTRACT BOOK Immediate Open Access Official journal of the – UEMS European Board and Section of Physical and Rehabilitation Medicine (EBPRM) – European Academy of Rehabilitation Medicine (EARM) – Baltic and North Sea Forum for Physical and Rehabilitation Medicine (BNFPRM) Published in association with the – European Society of Physical and Rehabilitation Medicine (ESPRM) – Canadian Association of Physical Medicine and Rehabilitation (CAPM&R) – Asia Oceania Society of Physical and Rehabilitation Medicine (AOSPRM) – Baltic and North Sea Forum for Physical and Rehabilitation Medicine (BNFPRM) Journal of Rehabilitation Medicine VOL. 51. OCTOBER 2019 Journal of Rehabilitation Medicine Journal of Rehabilitation Medicine is an international peer-review journal published in English with ten regular issues per year. It is owned by a Swedish nonprofit organi- zation: Foundation for Rehabilitation Information. Journal of Rehabilitation Medicine was former called Scandinavian Journal of Rehabilitation Medicine, which was founded by Olle Höök in 1968. The name was changed to Journal of Rehabilitation Medicine in 2001. Journal of Rehabilitation Medicine aims to be a leading worldwide forum for research in physical and rehabilitation medicine, aiming to increase